Yes, according the journal Neurology:
The authors caution that litigation’s effects could seriously impair efforts to identify compounds that contribute to a wide variety of diseases, including Parkinson’s disease, Alzheimer’s disease and amyotrophic lateral sclerosis (ALS). They provide suggestions for policy changes to help shield scientists and their research. Recommendations include enhancing privacy protections for patient data obtained in research projects and eliminating financial conflicts-of-interest for scientists actively involved in research related to the litigation.
